ABCAM Plc Abcam present at J.P. Morgan Healthcare Conference
January 08 2018 - 7:00AM
RNS Non-Regulatory
TIDMABC
ABCAM Plc
08 January 2018
8 January 2018
ABCAM PLC
("Abcam" or "the Company")
Abcam to present at the 36(th) Annual J.P. Morgan Healthcare
Conference
Cambridge, UK - Abcam plc (LSE: ABC), a global leader in the
supply of life science research tools, announces that Alan Hirzel,
Chief Executive Officer, will present at the 36th Annual J.P.
Morgan Healthcare Conference in San Francisco, California, on
Wednesday, January 10, 2018, at 16:30 Pacific Standard Time.
A live audio webcast of the presentation will be available on
Abcam's Investor website at
https://www.abcamplc.com/investors/reports-presentations/.
Subsequently, a replay of the webcast will be available on this
same website for approximately 90 days.
For further information please contact:
Abcam
+ 44 (0) 1223 696 000
James Staveley, Head of Investor Relations
james.staveley@abcam.com
FTI Consulting
+ 44 (0) 20 3727 1000
Ben Atwell / Brett Pollard / Natalie Garland-Collins
About Abcam plc
As an innovator in reagents and tools, Abcam's purpose is to
serve life science researchers globally to achieve their mission,
faster. Providing the research and clinical communities with tools
and scientific support, the Company offers highly validated
biological binders and assays to address important targets in
critical biological pathways.
Already a pioneer in data sharing and ecommerce in the life
sciences, Abcam's ambition is to be the most influential company in
life sciences by helping advance global understanding of biology
and causes of disease, which, in turn, will drive new treatments
and improved health. Two-thirds of the world's 750,000 life science
researchers use Abcam's affinity binders, reagents, biomarkers and
assays and the Company's products are mentioned in over 20,000 of
the 56,000 peer-reviewed papers published each year in the life
sciences.
By actively listening to and collaborating with researchers, the
Company continuously advances its portfolio to address their needs.
A transparent programme of customer reviews and datasheets,
combined with an industry-leading validation initiative, gives
researchers increased confidence in their results.
Abcam's eleven locations are located in the world's leading life
science research hubs, enabling local services and multi-language
support. Founded in 1998 and headquartered in Cambridge, UK, the
Company sells to more than 100 countries. Abcam was admitted to AIM
in 2005 (AIM: ABC).
To find out more, please visit www.abcam.com and
www.abcamplc.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRAEAEFPEFSPEFF
(END) Dow Jones Newswires
January 08, 2018 07:00 ET (12:00 GMT)
Abcam (LSE:ABC)
Historical Stock Chart
From Apr 2024 to May 2024
Abcam (LSE:ABC)
Historical Stock Chart
From May 2023 to May 2024